Tag archive for ‘Tsao Barclays Teva’
Shiri Habib-Valdhorn On Wednesday, July 30th, 2014

Barclays Pharmaceuticals Analyst: Teva Must Be Aggressive with Acquisitions

– Barclays analyst Douglas Tsao sees the success of double-dose Copaxone as a platform for expansion. – “The mergers and acquisition phenomenon is one of the most notable trends in the global pharmaceutical More...

Wordpress site Developed by Fixing WordPress Problems